Hathal Haddad, Head of Interventional Radiotherapy Unit at the Department of Radiation Oncology at University Hospital Tübingen, shared ESTRO’s post on LinkedIn:
“Interventional Radiotherapy (Brachytherapy) remains a highly relevant and continuously evolving pillar of modern prostate cancer care.
The sessions at ESTRO 2026 highlighted remarkable advances across the field:
- HDR and LDR Brachytherapy
- Workflow optimization
- Boost strategies
- Long-term clinical outcomes
- Salvage treatment approaches
Honored to contribute to advancing interventional radiotherapy and to supporting greater awareness of the unique value that Brachytherapy offers to our patients.
Together, we continue to improve precision, preserve quality of life, and expand treatment opportunities for men with prostate cancer.”
Quoting ESTRO’s post:
“Read this summary of the prostate cancer treatment advances covered in the ESTRO 26 brachytherapy track — covering presentations on HDR and LDR techniques, workflow optimisation, long-term outcomes, boost strategies, and salvage treatment.”
More posts featuring Hathal Haddad.